Equator Therapeutics vs Biogen
Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 biotech developing UCP1-activating thermogenesis drugs for obesity competing with GLP-1 agonists; seed-stage with proprietary HTS platform targeting brown fat calorie burning as next-generation anti-obesity mechanism.
About
Equator Therapeutics is a San Francisco-based early-stage biopharmaceutical company — backed by Y Combinator (W20) with seed funding from BioGenerator Ventures, Thoobik Holdings, Healthspan Capital, Endurance28, and Evolution VC Partners — developing first-in-class small molecule drugs that activate uncoupling protein 1 (UCP1) in brown and beige adipose tissue to increase metabolic rate and burn excess calories as heat, targeting obesity, metabolic syndrome, and related cardiometabolic diseases with a mechanism of action distinct from GLP-1 agonists (Ozempic, Wegovy) and traditional anti-obesity medications. Founded in 2019, Equator has developed a proprietary high-throughput drug discovery platform to identify selective UCP1 activators — compounds that safely activate the body's natural thermogenesis mechanism without the side effects (nausea, cardiovascular risk) that have limited previous metabolic drug programs.
Cambridge MA neuroscience biopharma (NASDAQ: BIIB) at $9.7B 2024 revenue; LEQEMBI $87M Q4 (Alzheimer's first-in-class amyloid therapy), SKYCLARYS $102M Q4 (Friedreich's ataxia), MS franchise declining vs. Eli Lilly donanemab.
About
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and commercializing therapies for neurological, neurodegenerative, and neurodevelopmental diseases including Alzheimer's disease, multiple sclerosis, spinal muscular atrophy, and rare neurological conditions through approximately 7,400 employees worldwide. In fiscal year 2024, Biogen reported total revenue of $9.7 billion (-2% year-over-year) and GAAP diluted EPS of $11.18 (+40%), reflecting significant cost-cutting that improved profitability despite modest revenue decline. Revenue decline was driven by continued erosion in the core multiple sclerosis franchise (TECFIDERA, AVONEX, TYSABRI facing generic and biosimilar competition) while new product revenue grew: LEQEMBI (lecanemab, Alzheimer's disease, partnered with Eisai) generated approximately $87 million in Q4 2024 global sales — reflecting the slow but building commercial trajectory of the first drug to slow Alzheimer's cognitive decline — and SKYCLARYS (omaveloxolone, Friedreich's ataxia) generated $102 million in Q4, nearly double the year-earlier period. CEO Christopher Viehbacher, who joined in 2022 from Genentech's parent Roche, has led a strategic restructuring that includes cost reduction, pipeline refocus on high-probability neurology programs, and the LEQEMBI commercial execution through a partnership model with Eisai.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.